Revance Therapeutics (RVNC) Downgraded to “Sell” at BidaskClub

BidaskClub lowered shares of Revance Therapeutics (NASDAQ:RVNC) from a hold rating to a sell rating in a research note published on Thursday morning.

RVNC has been the subject of a number of other research reports. ValuEngine lowered Revance Therapeutics from a buy rating to a hold rating in a research report on Thursday, September 27th. Cantor Fitzgerald restated a buy rating and set a $50.00 price objective on shares of Revance Therapeutics in a research report on Friday, September 14th. JMP Securities lowered Revance Therapeutics from an outperform rating to a market perform rating in a research report on Monday, September 17th. Piper Jaffray Companies restated a buy rating on shares of Revance Therapeutics in a research report on Monday, September 17th. Finally, Zacks Investment Research upgraded Revance Therapeutics from a hold rating to a buy rating and set a $33.00 price objective for the company in a research report on Wednesday, July 11th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $47.10.

NASDAQ:RVNC traded up $1.87 during midday trading on Thursday, reaching $24.88. 497,522 shares of the company traded hands, compared to its average volume of 182,601. Revance Therapeutics has a twelve month low of $21.45 and a twelve month high of $37.45.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $0.04. Revance Therapeutics had a negative return on equity of 57.81% and a negative net margin of 4,205.52%. The business had revenue of $2.36 million during the quarter, compared to analyst estimates of $0.49 million. Equities analysts expect that Revance Therapeutics will post -3.9 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in RVNC. Wells Fargo & Company MN boosted its position in Revance Therapeutics by 83.9% during the 1st quarter. Wells Fargo & Company MN now owns 25,635 shares of the biopharmaceutical company’s stock worth $789,000 after acquiring an additional 11,695 shares during the period. Northern Trust Corp boosted its position in Revance Therapeutics by 12.6% during the 1st quarter. Northern Trust Corp now owns 339,450 shares of the biopharmaceutical company’s stock worth $10,455,000 after acquiring an additional 38,045 shares during the period. The Manufacturers Life Insurance Company boosted its position in Revance Therapeutics by 12.5% during the 1st quarter. The Manufacturers Life Insurance Company now owns 20,446 shares of the biopharmaceutical company’s stock worth $630,000 after acquiring an additional 2,274 shares during the period. California State Teachers Retirement System boosted its position in Revance Therapeutics by 13.4% during the 1st quarter. California State Teachers Retirement System now owns 40,990 shares of the biopharmaceutical company’s stock worth $1,262,000 after acquiring an additional 4,858 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new position in Revance Therapeutics during the 1st quarter worth $189,000. Institutional investors own 94.32% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.

Read More: Why do companies issue stock splits?

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply